Editas Medicine, Inc.
CRISPR/CAS-related methods and compositions for treating sickle cell disease
Last updated:
Abstract:
CRISPR/CAS-related compositions and methods for treatment of Sickle Cell Disease (SCD) are disclosed.
Status:
Grant
Type:
Utility
Filling date:
26 Mar 2015
Issue date:
8 Feb 2022